Huvepharma swerves investor pushback and prices loan tight
Huvepharma, the Bulgarian animal drugs firm, has tightened pricing on its €180m six year term loan ‘B’, in a move that goes against the trend of investor pushback in the leveraged loan market.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: